Lantern Pharma reported its financial results for the second quarter of 2026, missing consensus loss estimates. Following the announcement of the wider-than-expected loss, the company's stock slipped in trading.
Additional details regarding revenue, operational expenses, and specific clinical pipeline updates from the earnings call were not immediately available.
